218 related articles for article (PubMed ID: 33992061)
1. Role of γ-Secretase Inhibitors for the Treatment of Diverse Disease Conditions through Inhibition of Notch Signaling Pathway.
Mondal A; Bose S; Banerjee S; Pal D
Curr Drug Targets; 2021; 22(15):1799-1807. PubMed ID: 33992061
[TBL] [Abstract][Full Text] [Related]
2. γ-Secretase in Alzheimer's disease.
Hur JY
Exp Mol Med; 2022 Apr; 54(4):433-446. PubMed ID: 35396575
[TBL] [Abstract][Full Text] [Related]
3. Quantification of gamma-secretase modulation differentiates inhibitor compound selectivity between two substrates Notch and amyloid precursor protein.
Yang T; Arslanova D; Gu Y; Augelli-Szafran C; Xia W
Mol Brain; 2008 Nov; 1():15. PubMed ID: 18983676
[TBL] [Abstract][Full Text] [Related]
4. γ-Secretase modulators exhibit selectivity for modulation of APP cleavage but inverse γ-secretase modulators do not.
Lessard CB; Rodriguez E; Ladd TB; Minter LM; Osborne BA; Miele L; Golde TE; Ran Y
Alzheimers Res Ther; 2020 May; 12(1):61. PubMed ID: 32430033
[TBL] [Abstract][Full Text] [Related]
5. γ-Secretase inhibitors and modulators.
Golde TE; Koo EH; Felsenstein KM; Osborne BA; Miele L
Biochim Biophys Acta; 2013 Dec; 1828(12):2898-907. PubMed ID: 23791707
[TBL] [Abstract][Full Text] [Related]
6. In vivo manifestation of Notch related phenotypes in zebrafish treated with Alzheimer's amyloid reducing gamma-secretase inhibitors.
Yang T; Arslanova D; Xu X; Li YM; Xia W
J Neurochem; 2010 Jun; 113(5):1200-9. PubMed ID: 20345767
[TBL] [Abstract][Full Text] [Related]
7. Γ-secretase modulators do not induce Aβ-rebound and accumulation of β-C-terminal fragment.
Li T; Huang Y; Jin S; Ye L; Rong N; Yang X; Ding Y; Cheng Z; Zhang J; Wan Z; Harrison DC; Hussain I; Hall A; Lee DH; Lau LF; Matsuoka Y
J Neurochem; 2012 Apr; 121(2):277-86. PubMed ID: 22035227
[TBL] [Abstract][Full Text] [Related]
8. Development and mechanism of γ-secretase modulators for Alzheimer's disease.
Crump CJ; Johnson DS; Li YM
Biochemistry; 2013 May; 52(19):3197-216. PubMed ID: 23614767
[TBL] [Abstract][Full Text] [Related]
9. Begacestat (GSI-953): a novel, selective thiophene sulfonamide inhibitor of amyloid precursor protein gamma-secretase for the treatment of Alzheimer's disease.
Martone RL; Zhou H; Atchison K; Comery T; Xu JZ; Huang X; Gong X; Jin M; Kreft A; Harrison B; Mayer SC; Aschmies S; Gonzales C; Zaleska MM; Riddell DR; Wagner E; Lu P; Sun SC; Sonnenberg-Reines J; Oganesian A; Adkins K; Leach MW; Clarke DW; Huryn D; Abou-Gharbia M; Magolda R; Bard J; Frick G; Raje S; Forlow SB; Balliet C; Burczynski ME; Reinhart PH; Wan HI; Pangalos MN; Jacobsen JS
J Pharmacol Exp Ther; 2009 Nov; 331(2):598-608. PubMed ID: 19671883
[TBL] [Abstract][Full Text] [Related]
10. Proton myo-inositol cotransporter is a novel γ-secretase associated protein that regulates Aβ production without affecting Notch cleavage.
Teranishi Y; Inoue M; Yamamoto NG; Kihara T; Wiehager B; Ishikawa T; Winblad B; Schedin-Weiss S; Frykman S; Tjernberg LO
FEBS J; 2015 Sep; 282(17):3438-51. PubMed ID: 26094765
[TBL] [Abstract][Full Text] [Related]
11. Discovery of notch-sparing gamma-secretase inhibitors.
Augelli-Szafran CE; Wei HX; Lu D; Zhang J; Gu Y; Yang T; Osenkowski P; Ye W; Wolfe MS
Curr Alzheimer Res; 2010 May; 7(3):207-9. PubMed ID: 20088802
[TBL] [Abstract][Full Text] [Related]
12. γ-Secretase modulators show selectivity for γ-secretase-mediated amyloid precursor protein intramembrane processing.
Weber TA; Lundkvist J; Wanngren J; Kvartsberg H; Jin S; Larssen P; Wu D; Oliveira DV; Minta K; Brinkmalm G; Zetterberg H; Blennow K; Nordvall G; Winblad B; Portelius E; Karlström H
J Cell Mol Med; 2022 Feb; 26(3):880-892. PubMed ID: 34931449
[TBL] [Abstract][Full Text] [Related]
13. Inhibition and modulation of gamma-secretase for Alzheimer's disease.
Wolfe MS
Neurotherapeutics; 2008 Jul; 5(3):391-8. PubMed ID: 18625450
[TBL] [Abstract][Full Text] [Related]
14. Second generation γ-secretase modulators exhibit different modulation of Notch β and Aβ production.
Wanngren J; Ottervald J; Parpal S; Portelius E; Strömberg K; Borgegård T; Klintenberg R; Juréus A; Blomqvist J; Blennow K; Zetterberg H; Lundkvist J; Rosqvist S; Karlström H
J Biol Chem; 2012 Sep; 287(39):32640-50. PubMed ID: 22851182
[TBL] [Abstract][Full Text] [Related]
15. γ-Secretase inhibitors and modulators for Alzheimer's disease.
Wolfe MS
J Neurochem; 2012 Jan; 120 Suppl 1(Suppl 1):89-98. PubMed ID: 22122056
[TBL] [Abstract][Full Text] [Related]
16. The Intracellular Domain of Amyloid Precursor Protein is a Potential Therapeutic Target in Alzheimer's Disease.
Nagase H; Nakayama K
Curr Drug Discov Technol; 2014; 11(4):243-58. PubMed ID: 25413946
[TBL] [Abstract][Full Text] [Related]
17. An improved cell-based method for determining the γ-secretase enzyme activity against both Notch and APP substrates.
McKee TD; Loureiro RM; Dumin JA; Zarayskiy V; Tate B
J Neurosci Methods; 2013 Feb; 213(1):14-21. PubMed ID: 23219895
[TBL] [Abstract][Full Text] [Related]
18. γ-Secretase-regulated mechanisms similar to notch signaling may play a role in signaling events, including APP signaling, which leads to Alzheimer's disease.
Nakayama K; Nagase H; Koh CS; Ohkawara T
Cell Mol Neurobiol; 2011 Aug; 31(6):887-900. PubMed ID: 21516353
[TBL] [Abstract][Full Text] [Related]
19. Selective amyloid-beta lowering agents.
Wolfe MS
BMC Neurosci; 2008 Dec; 9 Suppl 2(Suppl 2):S4. PubMed ID: 19090992
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of gamma-secretase as a therapeutic intervention for Alzheimer's disease: prospects, limitations and strategies.
Evin G; Sernee MF; Masters CL
CNS Drugs; 2006; 20(5):351-72. PubMed ID: 16696577
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
